2010
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial
Lu C, Lee JJ, Komaki R, Herbst RS, Feng L, Evans WK, Choy H, Desjardins P, Esparaz BT, Truong MT, Saxman S, Kelaghan J, Bleyer A, Fisch MJ. Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial. Journal Of The National Cancer Institute 2010, 102: 859-865. PMID: 20505152, PMCID: PMC2902826, DOI: 10.1093/jnci/djq179.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBiological ProductsCarcinoma, Non-Small-Cell LungCartilageChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm StagingRadiotherapy, AdjuvantTissue ExtractsTreatment OutcomeConceptsNon-small cell lung cancerStage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerProgression-free survivalTumor response rateCell lung cancerOverall survivalAE-941Lung cancerPlacebo groupClinical trialsUnresectable stage III NSCLC patientsResponse rateStage III NSCLC patientsPhase III clinical trialsAcademic oncology centerCommon grade 3Kaplan-Meier methodPhase III trialsShark cartilage extractTarget sample sizeToxic effectsChest radiotherapyConcurrent chemotherapyEligible patients
2008
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Varella-Garcia M, Gandara DR. Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy. Journal Of Clinical Oncology 2008, 26: 3351-3357. PMID: 18612151, PMCID: PMC3368372, DOI: 10.1200/jco.2007.14.0111.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabFemaleGene Expression Regulation, NeoplasticGenes, erbB-1HumansIn Situ HybridizationIn Situ Hybridization, FluorescenceLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm StagingPatient SelectionPredictive Value of TestsPrognosisProportional Hazards ModelsReference ValuesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsCell lung cancer patientsLung cancer patientsFISH-negative patientsEGFR FISHNSCLC patientsCancer patientsSurvival timeMedian progression-free survival timeProgression-free survival timeEGFR tyrosine kinase inhibitorsDisease control rateChemotherapy-naive patientsAdvanced-stage NSCLCMedian survival timeEpidermal growth factor receptor (EGFR) gene copy numberFISH-positive patientsAvailable tumor tissueEGFR gene copy numberTyrosine kinase inhibitorsFISH-positive tumorsPhase II selection trialFISH-positive groupConcurrent chemotherapyConcurrent therapyPredictive factors
2005
[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung Cancer
Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung Cancer. Journal Of Clinical Oncology 2005, 23: 1136-1143. PMID: 15718309, DOI: 10.1200/jco.2005.06.129.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalDisease-free survivalStandardized uptake valueLocal-regional controlHigh standardized uptake valueLower standardized uptake valuesCell lung cancerOverall survivalPrimary tumorPrognostic factorsPositron emission tomographyLung cancerBetter disease-free survivalEmission tomographyBetter DFS rateSignificant prognostic factorsKaplan-Meier methodStrong prognostic factorMetastasis-free survivalRegional lymph nodesBest discriminative valueLog-rank testSame cutoff pointIIIB NSCLCCurative surgery
2004
Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, Natale RB, Schiller JH, von Pawel J, Pluzanska A, Gatzemeier U, Grous J, Ochs JS, Averbuch SD, Wolf MK, Rennie P, Fandi A, Johnson DH. Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1. Journal Of Clinical Oncology 2004, 22: 777-784. PMID: 14990632, DOI: 10.1200/jco.2004.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCisplatinDeoxycytidineDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleGefitinibGemcitabineHumansLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedMultivariate AnalysisNeoplasm InvasivenessNeoplasm StagingProbabilityPrognosisQuinazolinesReference ValuesSurvival AnalysisTreatment OutcomeConceptsChemotherapy-naive patientsAdvanced NSCLCLung cancerAdvanced non-small cell lung cancerResponse rateNon-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor gefitinibEnd pointUnresectable stage IIICycles of chemotherapyEfficacy end pointPhase II trialFirst-line gemcitabineTyrosine kinase inhibitor gefitinibPhase I trialCell lung cancerUnexpected adverse eventsMedian survival timeKinase inhibitor gefitinibFurther preclinical testingDaily gefitinibFavorable tolerabilityII trialPlacebo groupAdverse eventsGefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, Scagliotti G, Rosell R, Oliff I, Reeves JA, Wolf MK, Krebs AD, Averbuch SD, Ochs JS, Grous J, Fandi A, Johnson DH. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. Journal Of Clinical Oncology 2004, 22: 785-794. PMID: 14990633, DOI: 10.1200/jco.2004.07.215.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugDrug Administration ScheduleFemaleGefitinibHumansInfusions, IntravenousLung NeoplasmsMaleMaximum Tolerated DoseMiddle AgedMultivariate AnalysisNeoplasm StagingPaclitaxelPredictive Value of TestsPrognosisQuinazolinesReference ValuesRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsResponse rateOverall survivalLung cancerActive epidermal growth factor receptor tyrosine kinase inhibitorAdvanced non-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsNon-small cell lung cancerReceptor tyrosine kinase inhibitorsDose-related diarrheaSignificant prolonged survivalUnexpected safety findingsChemotherapy-naive patientsDouble-blind trialPlacebo-controlled trialPhase II trialBaseline demographic characteristicsPhase I trialCell lung cancerConcentration/time curveTyrosine kinase inhibitorsCarboplatin areaDaily gefitinibGefitinib monotherapyMonotherapy trials
2000
Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.
Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clinical Cancer Research 2000, 6: 790-7. PMID: 10741698.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCadherinsCarcinoma, Non-Small-Cell LungDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansIn Situ HybridizationLung NeoplasmsMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Middle AgedMultivariate AnalysisNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingPredictive Value of TestsSurvival AnalysisConceptsE-cadherin ratioLung cancerType IV collagenaseLung carcinomaDisease outcomeStage I non-small cell lung carcinomaPrimary non-small cell lung cancerNon-small cell lung cancerE-cadherinKaplan-Meier survival analysisNon-small cell lung carcinomaD. Anderson Cancer CenterResectable lung cancerDisease-free survivalSignificant prognostic factorsLonger overall survivalCell lung cancerDisease recurrence rateRoutine histopathological examinationCox univariate analysisAnderson Cancer CenterCell lung carcinomaVascular endothelial growth factor/vascular permeability factorHuman lung cancerBasic fibroblast growth factor